Pacira BioSciences, Inc. Asset Resilience Ratio
Pacira BioSciences, Inc. asset resilience ratio. Pacira BioSciences, Inc. (PCRX) has an Asset Resilience Ratio of 3.63% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PCRX cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Pacira BioSciences, Inc. (2008–2025)
Asset resilience ratio of Pacira BioSciences, Inc. from 2008 to 2025. This chart shows how Pacira BioSciences, Inc.'s Asset Resilience Ratio has changed over time. Read debt load of Pacira BioSciences, Inc. for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Pacira BioSciences, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Pacira BioSciences, Inc.'s balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $45.16 Million | 3.63% |
| Total Liquid Assets | $45.16 Million | 3.63% |
Asset Resilience Insights
- Limited Liquidity: Pacira BioSciences, Inc. maintains only 3.63% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Pacira BioSciences, Inc. Industry Peers by Asset Resilience Ratio
Compare Pacira BioSciences, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Pacira BioSciences, Inc. Asset Resilience Ratio by Year (2008–2025)
Pacira BioSciences, Inc. asset resilience ratio by year from 2008 to 2025. The table below shows the annual Asset Resilience Ratio data for Pacira BioSciences, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.31% | $79.88 Million | $1.26 Billion | -7.06pp |
| 2024-12-31 | 13.38% | $207.84 Million | $1.55 Billion | +5.42pp |
| 2023-12-31 | 7.96% | $125.28 Million | $1.57 Billion | -3.02pp |
| 2022-12-31 | 10.98% | $184.51 Million | $1.68 Billion | +7.56pp |
| 2021-12-31 | 3.41% | $70.83 Million | $2.08 Billion | -29.67pp |
| 2020-12-31 | 33.09% | $421.70 Million | $1.27 Billion | +7.37pp |
| 2019-12-31 | 25.72% | $213.72 Million | $831.07 Million | -10.68pp |
| 2018-12-31 | 36.40% | $250.93 Million | $689.35 Million | -4.53pp |
| 2017-12-31 | 40.93% | $257.22 Million | $628.37 Million | +6.03pp |
| 2016-12-31 | 34.91% | $136.65 Million | $391.47 Million | +8.73pp |
| 2015-12-31 | 26.17% | $101.98 Million | $389.62 Million | -10.36pp |
| 2014-12-31 | 36.54% | $119.14 Million | $326.07 Million | +1.42pp |
| 2013-12-31 | 35.12% | $59.64 Million | $169.82 Million | +7.52pp |
| 2012-12-31 | 27.60% | $30.92 Million | $112.05 Million | +1.18pp |
| 2011-12-31 | 26.42% | $29.98 Million | $113.49 Million | +24.45pp |
| 2010-12-31 | 1.97% | $1.31 Million | $66.56 Million | -0.79pp |
| 2009-12-31 | 2.77% | $1.22 Million | $43.95 Million | +0.43pp |
| 2008-12-31 | 2.34% | $1.18 Million | $50.54 Million | -- |
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension ind… Read more